Literature DB >> 16136574

Comparison of pharmacokinetics of loxoprofen and its active metabolites after an intravenous, intramuscular, and oral administration of loxoprofen in rats: evidence for extrahepatic metabolism.

Tae-Sung Koo1, Dae-Hyun Kim, Sung-Hoon Ahn, Kang-Pil Kim, In-Wha Kim, Seung-Yong Seo, Young-Ger Suh, Dae-Duk Kim, Chang-Koo Shim, Suk-Jae Chung.   

Abstract

The objective of this study was to characterize the extent of the formation of the active (trans-alcohol form) and inactive (cis-alcohol) metabolites of loxoprofen and to compare the kinetics after its intragastric, intravenous, and intramuscular administrations in rats. After intravenous administration of the drug at doses of 5-20 mg/kg, the clearance and the volume of distribution for loxoprofen, and the ratios of the AUC for the metabolites to the parent drug were not statistically different with the dosage; the formation clearances were 1.08 and 0.87 mL/min/kg for the active and its isomeric metabolite, respectively. After the intragastric, intravenous, or intramuscular administration, AUC for loxoprofen and the metabolites at a dose of 10 mg/kg were not statistically different for the different routes of administration. The formation of the metabolites with the concomitant loss of loxoprofen was found in incubations with liver homogenates and blood but not with a muscle homogenate or plasma, indicating that the conversion of loxoprofen to the metabolites may occur both in the liver and extraheptic tissue(s). Thus, approximately 22% of the loxoprofen may have been converted to the active metabolite in the liver and the extraheptic tissue(s) and the pharmacokinetics of the active metabolite was independent of the route of administration. Copyright (c) 2005 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16136574     DOI: 10.1002/jps.20451

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

1.  CBR1 rs9024 genotype status impacts the bioactivation of loxoprofen in human liver.

Authors:  Adolfo Quiñones-Lombraña; Nasi Li; Virginia Del Solar; G Ekin Atilla-Gokcumen; Javier G Blanco
Journal:  Biopharm Drug Dispos       Date:  2018-06       Impact factor: 1.627

2.  Preclinical Pharmacokinetic Evaluation of β-Lapachone: Characteristics of Oral Bioavailability and First-Pass Metabolism in Rats.

Authors:  Iksoo Kim; Hyeongmin Kim; Jieun Ro; Kanghee Jo; Sandeep Karki; Prakash Khadka; Gyiae Yun; Jaehwi Lee
Journal:  Biomol Ther (Seoul)       Date:  2015-05-01       Impact factor: 4.634

3.  Efficacy and Safety of Loxoprofen Hydrogel Transdermal Patch Versus Loxoprofen Tablet in Chinese Patients with Myalgia: A Double-Blind, Double-Dummy, Parallel-Group, Randomized, Controlled, Non-Inferiority Trial.

Authors:  Dongbao Zhao; Zhiwei Chen; Shaoxian Hu; Jianhao Lin; Zengwu Shao; Guochun Wang; Weiguo Xiao; Yi Zheng; Zhiyi Zhang; Yeqing Shi; Zhanguo Li
Journal:  Clin Drug Investig       Date:  2019-04       Impact factor: 2.859

4.  Physiologically-Based Pharmacokinetic Modeling for Drug-Drug Interactions of Procainamide and N-Acetylprocainamide with Cimetidine, an Inhibitor of rOCT2 and rMATE1, in Rats.

Authors:  Yoo-Seong Jeong; Anusha Balla; Kwang-Hoon Chun; Suk-Jae Chung; Han-Joo Maeng
Journal:  Pharmaceutics       Date:  2019-03-06       Impact factor: 6.321

5.  Exploring the Metabolism of Loxoprofen in Liver Microsomes: The Role of Cytochrome P450 and UDP-Glucuronosyltransferase in Its Biotransformation.

Authors:  Riya Shrestha; Pil Joung Cho; Sanjita Paudel; Aarajana Shrestha; Mi Jeong Kang; Tae Cheon Jeong; Eung-Seok Lee; Sangkyu Lee
Journal:  Pharmaceutics       Date:  2018-08-02       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.